A Prospective study asssociating baseline gut microbiota as predictors of response to Ipilimumab in patients with metastatic melanoma

Trial Profile

A Prospective study asssociating baseline gut microbiota as predictors of response to Ipilimumab in patients with metastatic melanoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms GOLD
  • Most Recent Events

    • 10 Apr 2017 New trial record
    • 27 Mar 2017 Results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top